{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:04:04Z","timestamp":1786122244336,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of intensifying once\u2010weekly insulin icodec (icodec) with once\u2010weekly semaglutide in adults with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>ONWARDS 8 was a single\u2010arm, open\u2010label, treat\u2010to\u2010target, Phase 3b trial comprising a 26\u2010week icodec run\u2010in period and a 26\u2010week semaglutide intensification period. Eligible participants were adults with T2D (glycated haemoglobin [HbA1c]: 7.5%\u201310.5%) receiving daily basal insulin but not receiving a glucagon\u2010like peptide\u20101 receptor agonist. Following the run\u2010in period, participants with HbA1c levels &gt;\u20097.0% and \u2264\u200910.5% were eligible for treatment intensification with semaglutide up to 1.0\u2009mg. The primary endpoint was change in HbA1c from Week 26 (baseline) to Week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 148 participants were enrolled; 94 initiated semaglutide. From baseline to Week 52, mean HbA1c decreased from 7.88% (observed) to 6.66% (estimated), with an estimated mean change of \u22121.23%\u2010points (95% confidence interval: \u22121.39, \u22121.07%\u2010points;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Statistically significant changes from baseline to Week 52 were observed in 7\u2010point self\u2010measured blood glucose profile (\u22121.72\u2009mmol\/L), postprandial glucose increment (\u22121.31\u2009mmol\/L) and body weight (\u22123.85\u2009kg) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The relative decrease in mean weekly icodec dose from Week 25 to Week 52 was 24% (69.1% of participants had their icodec dose reduced by 20% at Week 26, per protocol). From baseline to Week 57 (end of trial), the rate of combined clinically significant or severe hypoglycaemia was 0.24 episodes per person\u2010year of exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intensification of icodec with semaglutide was feasible, with low rates of clinically significant or severe hypoglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT05813912<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71049","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:02:34Z","timestamp":1782964954000},"page":"8515-8522","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Intensifying Once\u2010Weekly Insulin Icodec Treatment With Once\u2010Weekly Semaglutide in Adults With Type 2 Diabetes: A Single\u2010Arm, Open\u2010Label, Treat\u2010to\u2010Target, Phase 3b Trial (\n                    <scp>ONWARDS<\/scp>\n                    8)"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-8674","authenticated-orcid":false,"given":"Krzysztof","family":"Strojek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze Medical University of Silesia  Zabrze Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Liebl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Center for Diabetes and Metabolism, m&amp;i\u2010Fachklinik  Bad Heilbrunn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha Narendra","family":"Mumbaikar","sequence":"additional","affiliation":[{"name":"Novo Nordisk Service Centre India Private Ltd  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stinne Byrholdt","family":"S\u00f8gaard","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kehlet Watt","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Philis\u2010Tsimikas","sequence":"additional","affiliation":[{"name":"Scripps Whittier Diabetes Institute  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14871"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303208"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00093-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11313"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00520-2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1288"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16328"},{"key":"e_1_2_10_12_1","unstructured":"World Medical Association \u201cWMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants \u201d 2024 https:\/\/www.wma.net\/policies\u2010post\/wma\u2010declaration\u2010of\u2010helsinki\/."},{"key":"e_1_2_10_13_1","unstructured":"International Council for Harmonisation \u201cIntegrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Current Step 4 Version \u201d 2016."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13859"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14522"},{"key":"e_1_2_10_18_1","first-page":"S378","article-title":"Semaglutide Consistently Reduces Both Fasting and Postprandial Glucose Levels Across SUSTAIN 1\u20135 Clinical Trials","volume":"60","author":"Cariou B. U. J.","year":"2017","journal-title":"Diabetologia"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13120"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14765"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_10_22_1","volume-title":"Summary of Product Charactersitics","author":"Novo Nordisk A\/S","year":"2025"},{"key":"e_1_2_10_23_1","volume-title":"Prescribing Information, Ozempic","author":"Novo Nordisk Inc","year":"2025"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:51:46Z","timestamp":1786092706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.71049"],"URL":"https:\/\/doi.org\/10.1111\/dom.71049","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}